AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18284670 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-help course (8-week duration, moderated, individual feedback via e-mail)
Number of subjects: 286
Study 18284670 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-help course
Number of subjects: 286
Study 18284670 — intervention group
Group type: COMPARATOR
Intervention: Control group (wait-list)
Number of subjects: 286
Study 14594748 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg/day for the first 28 days and 10 mg/day thereafter)
Number of subjects: 67
Study 14594748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 9707356 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg PETN
Number of subjects: 12
Study 9707356 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg PETN
Number of subjects: 12
Study 9707356 — intervention group
Group type: COMPARATOR
Intervention: 0.4 mg GTN
Number of subjects: 12
Study 7536138 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine, RNA, and omega-3 fatty acids supplemented diet
Number of subjects: 42
Study 7536138 — intervention group
Group type: COMPARATOR
Intervention: Placebo diet
Number of subjects: 42
Study 2650539 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg lovastatin twice daily for 6 weeks
Number of subjects: 10
Study 2650539 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg lovastatin twice daily for 6 weeks
Number of subjects: 10
Study 2650539 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg lovastatin twice daily for 6 weeks
Number of subjects: 10
Study 2650539 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg lovastatin twice daily
Number of subjects: 10
Study 2650539 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg lovastatin twice daily
Number of subjects: 10
Study 2650539 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg lovastatin twice daily
Number of subjects: 10
Study 2650539 — intervention group
Group type: COMPARATOR
Intervention: Placebo for the first 6 weeks followed by stepped doses of lovastatin
Number of subjects: 10
Study 361152 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid mixture
Number of subjects: 55
Study 361152 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkali mixture
Number of subjects: 55
Study 361152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 31583989 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD participants with childhood maltreatment (DM+)
Number of subjects: 285
Study 31583989 — intervention group
Group type: COMPARATOR
Intervention: MDD participants without maltreatment (DM-)
Number of subjects: 285
Study 31583989 — intervention group
Group type: COMPARATOR
Intervention: Healthy participants without maltreatment (HM-)
Number of subjects: 285
Study 31583989 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment remitted DM+
Number of subjects: 285
Study 31583989 — intervention group
Group type: COMPARATOR
Intervention: Post-treatment remitted DM-
Number of subjects: 285
Study 31102328 — intervention group
Group type: EXPERIMENTAL
Intervention: High oxygen therapy (≥96% SpO2)
Number of subjects: 50
Study 31102328 — intervention group
Group type: COMPARATOR
Intervention: Low oxygen therapy (90–92% SpO2)
Number of subjects: 50
Study 26920551 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived needs for housing
Number of subjects: 165
Study 26920551 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived needs for substance treatment services
Number of subjects: 165
Study 26920551 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived needs for assistance/benefits
Number of subjects: 165
Study 26920551 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived needs for mental health counseling
Number of subjects: 165
Study 25500985 — intervention group
Group type: EXPERIMENTAL
Intervention: Limbal incision
Number of subjects: 120
Study 25500985 — intervention group
Group type: COMPARATOR
Intervention: Fornix incision
Number of subjects: 120
Study 25500985 — intervention group
Group type: COMPARATOR
Intervention: Between-group comparison
Number of subjects: 120
Study 23271030 — intervention group
Group type: COMPARATOR
Intervention: Sublingual sufentanil 15 µg
Number of subjects: 195
Study 23271030 — intervention group
Group type: COMPARATOR
Intervention: Sublingual sufentanil 10 µg
Number of subjects: 195
Study 23271030 — intervention group
Group type: COMPARATOR
Intervention: Sublingual sufentanil 5-15 µg
Number of subjects: 195
Study 21980881 — intervention group
Group type: EXPERIMENTAL
Intervention: Deepwave treatment
Number of subjects: 23
Study 21980881 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (Control)
Number of subjects: 23
Study 19153678 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate (2 g/day)
Number of subjects: 1649
Study 19153678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1649
Study 16709243 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention consisting of 18 sessions in 6 separate programmes
Number of subjects: 0
Study 16709243 — intervention group
Group type: COMPARATOR
Intervention: Ethnic control group
Number of subjects: 0
Study 16709243 — intervention group
Group type: COMPARATOR
Intervention: Single white control group
Number of subjects: 0
Study 14748817 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg daily for 5 days)
Number of subjects: 10
Study 14748817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11695526 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 0
Study 11695526 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar patients
Number of subjects: 0
Study 9042992 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (0.3 mg/kg)
Number of subjects: 36
Study 9042992 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (0.3 mg/kg)
Number of subjects: 36
Study 9042992 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sterile saline)
Number of subjects: 36
Study 16353616 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (60 mg/d)
Number of subjects: 38
Study 16353616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 16353616 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Fluoxetine and Placebo)
Number of subjects: 38
Study 30087555 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg fimasartan
Number of subjects: 36
Study 30087555 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg atorvastatin
Number of subjects: 36
Study 30087555 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of fimasartan and atorvastatin
Number of subjects: 36
Study 25763853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of hyaluronic acid (HA) post-operatively
Number of subjects: 35
Study 25763853 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic microfracture surgery alone
Number of subjects: 35
Study 23804543 — intervention group
Group type: EXPERIMENTAL
Intervention: RYGB surgery
Number of subjects: 0
Study 23804543 — intervention group
Group type: COMPARATOR
Intervention: Obese subjects and obese T2DM patients
Number of subjects: 0
Study 23270248 — intervention group
Group type: EXPERIMENTAL
Intervention: Kang'ai injection with chemotherapy
Number of subjects: 42
Study 23270248 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only (Control)
Number of subjects: 42
Study 20440030 — intervention group
Group type: EXPERIMENTAL
Intervention: Golfing
Number of subjects: 18
Study 20440030 — intervention group
Group type: EXPERIMENTAL
Intervention: Lawn Mowing
Number of subjects: 18
Study 19855323 — intervention group
Group type: EXPERIMENTAL
Intervention: Weightlifting
Number of subjects: 29
Study 19855323 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometrics
Number of subjects: 29
Study 19855323 — intervention group
Group type: COMPARATOR
Intervention: Weight training
Number of subjects: 29
Study 16480123 — intervention group
Group type: EXPERIMENTAL
Intervention: Collective self-prime
Number of subjects: 0
Study 16480123 — intervention group
Group type: EXPERIMENTAL
Intervention: Relational self-prime
Number of subjects: 0
Study 16480123 — intervention group
Group type: COMPARATOR
Intervention: Private self-prime
Number of subjects: 0
Study 12759389 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (25 mg)
Number of subjects: 864
Study 10974724 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 8-Gy fraction
Number of subjects: 90
Study 10974724 — intervention group
Group type: COMPARATOR
Intervention: 20 Gy in five fractions
Number of subjects: 90
Study 9092145 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 1749
Study 9092145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1749
Study 8481254 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) with or without dipyridamole (D)
Number of subjects: 17
Study 8481254 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole (D)
Number of subjects: 17
Study 8481254 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulants (AC)
Number of subjects: 17
Study 8481254 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA)
Number of subjects: 17
Study 8481254 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) + Anticoagulants (AC)
Number of subjects: 17
Study 8481254 — intervention group
Group type: EXPERIMENTAL
Intervention: Low (100 mg) to medium (325 mg) daily aspirin dosage
Number of subjects: 17
Study 8481254 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postoperative treatment (< or = 6 h)
Number of subjects: 17
Study 8481254 — intervention group
Group type: COMPARATOR
Intervention: Preoperative administration of aspirin
Number of subjects: 17
Study 8481254 — intervention group
Group type: COMPARATOR
Intervention: Any antithrombotic therapy
Number of subjects: 17
Study 3538880 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% hydroxypropyl methylcellulose
Number of subjects: 70
Study 3538880 — intervention group
Group type: COMPARATOR
Intervention: 1% sodium hyaluronate
Number of subjects: 70
Study 29672392 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxygenated fatty acids (HOFAs) treatment
Number of subjects: 174
Study 29672392 — intervention group
Group type: COMPARATOR
Intervention: Control (no HOFAs applied)
Number of subjects: 174
Study 26969090 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg per day orally for 54 weeks
Number of subjects: 1943
Study 26969090 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg twice per day orally for 54 weeks
Number of subjects: 1943
Study 26969090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1943
Study 25377986 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocautery (EC)
Number of subjects: 36
Study 25377986 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency tissue reduction (RFTR)
Number of subjects: 36
Study 22435470 — intervention group
Group type: EXPERIMENTAL
Intervention: SLS-free dentifrice
Number of subjects: 90
Study 22435470 — intervention group
Group type: COMPARATOR
Intervention: SLS-containing dentifrice (SLS-A and SLS-B)
Number of subjects: 90
Study 20485880 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (zinc and vitamin A)
Number of subjects: 0
Study 20485880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18517133 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimecaine 50 mg with 4 mg morphine administered epidurally in 8 hour intervals
Number of subjects: 150
Study 18517133 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.25% and fentanyl 2 microg/ml administered at an infusion rate of 8 ml/h
Number of subjects: 150
Study 18517133 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimecaine with morphine
Number of subjects: 150
Study 16111417 — intervention group
Group type: EXPERIMENTAL
Intervention: Coblation tonsillotomy
Number of subjects: 18
Study 16111417 — intervention group
Group type: COMPARATOR
Intervention: Coblation tonsillectomy
Number of subjects: 18
Study 11950105 — intervention group
Group type: EXPERIMENTAL
Intervention: Activation of illness concern
Number of subjects: 0
Study 11950105 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical control for state anxiety
Number of subjects: 0
Study 10522523 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ACTH (0.005 mg/kg per day)
Number of subjects: 25
Study 10522523 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ACTH (0.025 mg/kg per day)
Number of subjects: 25
Study 8748907 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate 70 mg/kg (group A)
Number of subjects: 97
Study 8748907 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate 100 mg/kg (group B)
Number of subjects: 97
Study 1823061 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified distal splenorenal shunt (DSRS)
Number of subjects: 100
Study 1823061 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sclerotherapy (ES)
Number of subjects: 100
Study 7025554 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 12‐50 microgram/min of salbutamol (Ventoline) and 4 mg orally at 4‐hour intervals
Number of subjects: 108
Study 7025554 — intervention group
Group type: COMPARATOR
Intervention: Fenoterol, 3‐4 microgram/min and subsequently 5 mg orally at 4‐hour intervals
Number of subjects: 108
Study 30094611 — intervention group
Group type: EXPERIMENTAL
Intervention: Plate fixation
Number of subjects: 0
Study 30094611 — intervention group
Group type: COMPARATOR
Intervention: Intramedullary pin fixation
Number of subjects: 0
Study 28230742 — intervention group
Group type: EXPERIMENTAL
Intervention: GLU + FRU (1.2 g∙min‐1 glucose + 0.6 g∙min‐1 fructose)
Number of subjects: 10
Study 28230742 — intervention group
Group type: EXPERIMENTAL
Intervention: GLU + SUC (0.6 g∙min‐1 glucose + 1.2 g∙min‐1 sucrose)
Number of subjects: 10
Study 28230742 — intervention group
Group type: COMPARATOR
Intervention: GLU (1.8 g∙min‐1 glucose)
Number of subjects: 10
Study 25912752 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin 3-hour infusion (T3h)
Number of subjects: 133
Study 25912752 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin 24-hour infusion (T24h)
Number of subjects: 133
Study 25912752 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 133
Study 23360657 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation breathing exercise (RB)
Number of subjects: 26
Study 23360657 — intervention group
Group type: COMPARATOR
Intervention: Control breathing (CB)
Number of subjects: 26
Study 21355070 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 100
Study 18808733 — intervention group
Group type: EXPERIMENTAL
Intervention: Home HIOH intervention
Number of subjects: 415
Study 18808733 — intervention group
Group type: COMPARATOR
Intervention: Telephone HIOH intervention
Number of subjects: 415
Study 18808733 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 415
Study 17066400 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment
Number of subjects: 0
Study 17066400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15513495 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intraarticular morphine 20 mg/mL, 0.5 mL plus ropivacaine 2 mg/mL, 100 mL; bolus 20 mL and 2 mL/hour from 24 to 72 hours postoperatively (group 2)
Number of subjects: 154
Study 15513495 — intervention group
Group type: EXPERIMENTAL
Intervention: Double the dose of continuous intraarticular morphine and ropivacaine (4 mL/hour from 24 to 72 hours postoperatively) (group 3)
Number of subjects: 154
Study 15513495 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative analgesics (group 1)
Number of subjects: 154
Study 15513495 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intraarticular morphine and ropivacaine (group 2 and group 3)
Number of subjects: 154
Study 10930961 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 28
Study 10930961 — intervention group
Group type: COMPARATOR
Intervention: Saquinavir
Number of subjects: 28
Study 10930961 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir
Number of subjects: 28
Study 10930961 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil coadministered with saquinavir or ritonavir
Number of subjects: 28
Study 9049554 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg
Number of subjects: 40
Study 9049554 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 8339808 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study 2883777 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasodilators (including nitrates and alpha-receptor blocking agents)
Number of subjects: 0
Study 2883777 — intervention group
Group type: EXPERIMENTAL
Intervention: Converting enzyme inhibitors
Number of subjects: 0
Study 2883777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31506921 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracker on
Number of subjects: 8
Study 28234719 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper and Lower Body (ULB) PAP
Number of subjects: 11
Study 28234719 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower Body (LB) PAP
Number of subjects: 11
Study 28234719 — intervention group
Group type: COMPARATOR
Intervention: Usual Competition (CON) Warm-Up Routine
Number of subjects: 11
Study 28110949 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetazolamide (500 mg) administration 1 hour preoperatively
Number of subjects: 90
Study 28110949 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetazolamide (500 mg) administration 3 hours postoperatively
Number of subjects: 90
Study 28110949 — intervention group
Group type: COMPARATOR
Intervention: No acetazolamide administration
Number of subjects: 90
Study 25682211 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselor-assisted problem solving (CAPS), predominantly online intervention
Number of subjects: 132
Study 25682211 — intervention group
Group type: COMPARATOR
Intervention: Internet resource comparison (control group)
Number of subjects: 132
Study 24101198 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual action effects
Number of subjects: 0
Study 24101198 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive action effects
Number of subjects: 0
Study 24101198 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermodal integration
Number of subjects: 0
Study 24101198 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbation of cursor amplitude or hand amplitude
Number of subjects: 0
Study 21418045 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal hyperbaric bupivacaine 7.5 mg
Number of subjects: 90
Study 21418045 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal hyperbaric bupivacaine 7.5 mg followed by epidural volume extension with saline 5 ml
Number of subjects: 90
Study 21418045 — intervention group
Group type: COMPARATOR
Intervention: Spinal hyperbaric bupivacaine 10 mg without epidural volume extension
Number of subjects: 90
Study 18581058 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers (317 patients)
Number of subjects: 499
Study 18581058 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers (182 patients)
Number of subjects: 499
Study 17175547 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Oral Contraceptives (COC)
Number of subjects: 4200
Study 17175547 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethindrone Enanthate (NET-EN)
Number of subjects: 4200
Study 17175547 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot Medroxyprogesterone Acetate (DMPA)
Number of subjects: 4200
Study 17175547 — intervention group
Group type: COMPARATOR
Intervention: No hormonal method
Number of subjects: 4200
Study 17175547 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA duration
Number of subjects: 4200
Study 15124187 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial thickness measurement (transvaginal sonography)
Number of subjects: 95
Study 15124187 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial thickness > 9 mm
Number of subjects: 95
Study 15124187 — intervention group
Group type: EXPERIMENTAL
Intervention: Time since menopause < 5 years
Number of subjects: 95
Study 15124187 — intervention group
Group type: EXPERIMENTAL
Intervention: Time since menopause > 15 years
Number of subjects: 95
Study 15124187 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutoff points for diagnostic biopsy
Number of subjects: 95
Study 15124187 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple logistic regression analysis
Number of subjects: 95
Study 12136518 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast conservation therapy (BCT) with lumpectomy and radiation
Number of subjects: 0
Study 12136518 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by BCT
Number of subjects: 0
Study 12136518 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy radiation for early breast cancer patients with 1 to 3 positive lymph nodes
Number of subjects: 0
Study 12136518 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of chest wall and regional lymphatic irradiation to adjuvant systemic therapy
Number of subjects: 0
Study 10051931 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 31
Study 10051931 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 31
Study 7977523 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin therapy (200 micrograms intranasally twice a day for 3 months)
Number of subjects: 173
Study 7977523 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin therapy (200 micrograms intranasally twice a day for 6 months)
Number of subjects: 173
Study 7977523 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin therapy (both 3 and 6 months)
Number of subjects: 173
Study 7977523 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin therapy
Number of subjects: 173
Study 2599698 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented Charnley prosthesis
Number of subjects: 21
Study 2599698 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cemented HP-Garches prosthesis
Number of subjects: 21
Study 29655290 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 5 mg
Number of subjects: 27